Therapeutic Solutions International Inc - TSOI stock
OTC Symbol: TSOI | OTC Tier: Pink Current
About TSOI[edit]
Therapeutic Solutions International, Inc. (OTC: TSOI) is a biomedical company focused on developing and commercializing innovative therapies for a variety of medical conditions. The company was founded in 2015 and is headquartered in Oceanside, California, USA. TSOI is engaged in the research and development of a number of therapies targeting various diseases, including cancer, neurological disorders, autoimmune disorders, and infectious diseases.[1]
Products[edit]
Some of the key products and therapies under development by the company include:[2]
- StemVacs: a cancer vaccine platform that utilizes a patient's own stem cells to stimulate an immune response against cancer cells
- NanoStilbene: a nanoformulation of the antioxidant resveratrol that has been shown to have potential therapeutic effects in a variety of diseases
- QuadraMune: an immunomodulatory therapy designed to boost the immune system's response to infectious diseases and cancer
- Saliva COVID-19 Rapid Test: a rapid antigen test for COVID-19 that uses saliva samples instead of nasal swabs.
Parnterships[edit]
In addition to its research and development efforts, TSOI has also entered into a number of partnerships and collaborations with other companies and academic institutions. These collaborations are focused on further advancing the company's product pipeline and commercializing its therapies.
Patents[edit]
The company has filed over 50 patent applications for a variety of treatments including cancer and Parkinson's disease, as well as preventing pregnancy complications.[3]
Summary[edit]
Overall, TSOI is focused on developing innovative therapies that have the potential to address significant unmet medical needs. The company is still in the early stages of development and its products are not yet commercially available, but it has demonstrated promising results in preclinical studies and clinical trials, and has generated significant interest from investors and the biomedical community.
